Author: hannametrami
Q&A with OWise User: Jenny
Jenny is an OWise user that has been part of user testing for the latest version of the app. Read her thoughts on OWise here.
Coping with guilt through expressive writing
Guilt is a complex emotion: it can come in many different forms and can be experienced for a variety of different reasons in the context of cancer, as well as in other aspects of life.
Coping with guilt through expressive writing
Guilt is a complex emotion: it can come in many different forms and can be experienced for a variety of different reasons in the context of breast cancer, as well as in other aspects of life.
HER2 and Herceptin®: A Look at the History
The discovery of the HER2 gene led to the development of Herceptin®: a targeted therapy that is widely used today for HER2+ breast cancer patients.
Recordings or summaries of consultations for people with cancer (Review)
Pitkethly et al., 2008; Cochrane Library. This review examined the effects of giving people with cancer audio recordings or written summaries of consultations.
The characteristics and effectiveness of Question Prompt List interventions in oncology: a systematic review of the literature
Brandes et al., 2014; Journal of the Psychological, Social and Behavioural Dimensions in Cancer. Systematic review examining the effectiveness of Question Prompt Lists in oncology.
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Basch et al., 2016; Journal of Clinical Oncology. A RCT that investigated symptom monitoring with PROs during cancer treatment.
Overall Survival Results of Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Basch et al., 2017; JAMA. A trial investigating the effect of PROs on symptom monitoring during routine cancer treatment.
Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT)
Lidington et al., 2020; BMC. OWise is being assessed by the randomised clinical trial ADAPT at the Royal Marsden NHS Foundation Trust. Find out more here:
CE-marked: Class I Medical Device
OWise was CE-marked to comply with the European regulatory standards for safety and usage on the 7th of May, 2014.
NHS approved
OWise is one in five cancer apps listed in the NHS app library.
What are monoclonal antibodies?
There is a lot of terminology that comes with a breast cancer diagnosis. Explore how monoclonal antibodies such as Herceptin® work and how to recognise them!